LHX2は,前立腺がんにおける腫瘍の進行を促すための代謝と表遺伝的経路を再構築する
Jun Jiang1, Shaojie Liu1, Chao Xu1
1Xijing Hospital, Xi'an, None Selected, China.
Cancer research
|September 3, 2025
まとめ
神経内分泌前立腺がん (NEPC) の進行を促すのは,糖分分解とLHX2を含む代謝-表遺伝的フィードバックループです. この経路を標的として パリタプレヴィールを用いると 侵襲的な前立腺がんの治療戦略が生まれます
科学分野:
- 腫瘍学
- 代謝経路
- エピジェネティクス
背景:
- 神経内分泌前立腺がん (NEPC) は,アンドロゲン欠乏療法中にしばしば発症する攻撃的なサブタイプです.
- NEPCの現在の管理戦略は限られている.
- NEPCの進行の根本的なメカニズムを理解することは,効果的な治療法の開発に不可欠です.
研究 の 目的:
- 前立腺がんがNEPCに進行する代謝-表遺伝的メカニズムを解明する.
- NEPC治療の潜在的治療標的を特定する.
主な方法:
- 前立腺がんにおける糖分解と転写因子LHX2の相互作用を調査した.
- アンドロゲン受容体 (AR) を抑制するために使用されたエンザルタミドと,グリコリチス酵素に対する観察された効果.
- 乳酸の蓄積,ヒストンの乳化,LHX2の発現を評価した.
- LDHAとDNMT1の発現を調節するLHX2の役割を調べた.
- LHX2とNEPCマーカーに対するパリタプレビルの効果を評価した.
主要な成果:
- 乳酸とヒストンの乳化が増加し,LHX2発現が増加した.
- LHX2は転写的にLDHAを活性化させ,乳酸の産生を増強し,DNMT1を増加させ,神経内分泌遺伝子の発現を促進した.
- パリタプレビールはLHX2に直接結合し,神経内分泌マーカーの発現と腫瘍の進行を抑制する.
結論:
- グライコリシスとLHX2の間のポジティブなフィードバックループは,NEPCの発達と進行を促進します.
- LHX2は,NEPCの表型を編成する上で重要な役割を果たします.
- パリタプレビルは,LHX2を標的としてNEPCの治療薬としての可能性を示しています.
さらに関連する動画
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.9K
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.1K
関連する概念動画
Epigenetic Regulation
3.1K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.1K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
